采纳股份(301122) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between 48 million and 62 million yuan, a decrease of 44.92% compared to the same period last year [3]. - The net profit after deducting non-recurring losses is projected to be between 28 million and 40 million yuan, down 52.86% year-on-year [3]. - The estimated operating revenue for 2024 is approximately 388 million yuan, reflecting a decline of about 5% compared to the previous year [5]. Market Challenges - The company faced challenges due to an import warning from the U.S. FDA, impacting the ability to enter the U.S. market with certain medical syringe products [5]. - The overseas project factory has not yet been completed and put into production, resulting in no business or performance contribution from this project in 2024 [6]. Audit and Risk Management - The impairment provisions for affected inventories and receivables will be determined after audit by the appointed auditing firm [6]. - The performance forecast data is preliminary and has not been audited by the annual report auditing agency [7]. - The company emphasizes the importance of cautious decision-making for investors due to the potential risks involved [7].